TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02753075

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Rinse
Description: Oral rinse containing 0% w/w KOX 0ppm F, pH 4.5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste
Description: Oral rinse containing 1000ppm fluoride as sodium monofluorophosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste
Description: Oral rinse containing 1000ppm fluoride as sodium monofluorophosphate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride toothpaste
Description: Oral rinse containing 1000ppm fluoride as sodium monofluorophosphate
Study: NCT02583932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meaning-Making intervention (MMi)
Description: The MMi is a brief, individualized and manualized therapeutic approach based on post-trauma literature and designed to facilitate a search for meaning following a cancer diagnosis.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Empathic Visitor
Description: They will provide the basic ingredients for fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing.
Study: NCT00258076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE
Study: NCT00357188

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir Sulphate + Ritonavir
Description: Capsules, Oral, ATV 300 mg + RTV 100 mg, once daily, 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir Sulphate + Ritonavir + Efavirenz
Description: Capsules/Tablets, oral, ATV 400 mg + RTV 100 mg + EFV 600 mg, once daily, 14 days.
Study: NCT00187746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil
Description: Subjects will be given a single oral dose of 10 mg of adefovir dipivoxil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil
Description: Subjects will be given a single oral dose of 10 mg of adefovir dipivoxil
Study: NCT01165866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment 1. Metoclopramide
Description: metoclopramide 0.3mg/kg maximum dose 10mg will be added in the burette and mixed with normal saline to make up 50cc of medication for intravenous administration.

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment 2 Ondansetron
Description: Single dose of Ondansetron 0.15 mg/kg
Study: NCT03531216

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rosemary essential oil
Description: Topically-applied oil to both dorsal and palmar aspects of the hands

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topically-applied oil to both dorsal and palmar aspects of the hands
Study: NCT06310850

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Patients will be administered 0.15 mg kg-1 intravenous ketamine (The sample provided contains equal proportions of two enantiomers, S and R ketamine hydrochloride.) 3 minutes before thoracic epidural catheter placement.
Study: NCT01728857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Zeltiq System
Description: Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
Study: NCT06310850

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous saline will be administered to patients 3 minutes before the thoracic epidural catheter is placed.
Study: NCT04395937

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercises
Description: One hour twice a week to practice respiratory exercises, postural exercises, muscular exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: One hour twice a week to practice respiratory exercises, postural exercises, muscular exercises
Study: NCT03773731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT)
Description: Exercise training on bicycle ergometer with high intensity bouts of 1 min interspersed by low intensity recovery intervals

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity continuous training (MICT)
Description: Exercise training on bicycle ergometer with moderate intensity (60 - 65 % of individual maximal power output)
Study: NCT03978364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine combined HHT
Description: Azacitidine 75mg/m2，iH，qd×7days，HHT，3mg/m2 ivdrip qd×3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine regimen
Description: Azacitidine 75mg/m2，iH，qd×7days，28 days a cycle
Study: NCT04470999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Blood collection and PBMC collection via apheresis machine will be conducted
Study: NCT01108588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo (to match Clopidogrel)
Description: Placebo (grossly matched Clopidogrel 75 mg) daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo (to match Clopidogrel)
Description: Placebo (grossly matched Clopidogrel 75 mg) daily
Study: NCT02978742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Recovery Record App
Description: Participants will use the Recovery Record smartphone app, which is a meal monitoring tool, that incorporates discrete reminders, motivational tools, social support, summative feedback, and coping skill suggestions. Participants will also receive tailored, algorithm-generated content in a structured manner that mimics the progression of psychotherapy (e.g., checking in with users, reminding them of their reasons for wanting to recover, and working towards goals) over the course of 8 weeks.
Study: NCT02978742

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive Recovery Record App
Description: Participants will use the Recovery Record smartphone app, which is a meal monitoring tool, that incorporates discrete reminders, motivational tools, social support, summative feedback, and coping skill suggestions. Participants will also receive tailored, algorithm-generated content in a structured manner that mimics the progression of psychotherapy (e.g., checking in with users, reminding them of their reasons for wanting to recover, and working towards goals) over the course of 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized Coaching
Description: Coaches (dietitians or mental health clinicians) will review patients' logs daily and participants will receive one communication of standardized feedback each day through the app based on their food records. A standardized feedback manual to be used by coaches has been developed by co-investigators (two PhD psychologists and one psychiatrist), and all feedback will be monitored for consistency and quality by co-investigators.
Study: NCT01412866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EDSS with CO feedback and health checklist
Description: Web-based electronic decision support system with CO feedback and health-checklist

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EDSS with health checklist feedback alon
Description: Web-based electronic decision support system (EDSS) with health-checklist feedback alone (without CO feedback)
Study: NCT01108588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo (to match Clopidogrel)
Description: Placebo (grossly matched Clopidogrel 75 mg) daily
Study: NCT00663052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: ETN 50 mg QW + PBO QW for 12 weeks followed by ETN 50 mg QW for 12 weeks.
Study: NCT01401179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefazolin, erythromycin, clarithromycin
Description: Antibiotics regimen was one of cefazolin or cefazolin plus erythromycin or cefazolin plus clarithromycin. Intravenous 1g cefazolin was given every 6 hours after negative result skin test for allergic reaction. With cefazolin plus erythromycin group or cefazolin plus clarithromycin, cefazolin was given with same protocol and 250mg oral erythromycin every 6 hours or 500mg oral clarithromycin every 12 hours was added. All antibiotics were given for 7 days or until delivery.
Study: NCT00663052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: ETN 50 mg BIW for 12 weeks folowed ETN 50 mg QW for 12 weeks.
Study: NCT02776228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brotizolam
Description: Every patient which will enroll to the study will fill up The Pittsburgh Sleep Quality Index in there admission to the cardiac surgery unit. in the discharge day the patient will receive 0.25 mg brotizolam once a day before sleep for six weeks. one week and six weeks after discharge day, there is routine follow up in our outpatient clinic. in those appointed time the patient will fill again The Pittsburgh Sleep Quality Index.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Every patient which will enroll to the study will fill up The Pittsburgh Sleep Quality Index in there admission to the cardiac surgery unit. in the discharge day the patient will receive 0.25 mg LACTOSE once a day before sleep for six weeks. one week and six weeks after discharge day, there is routine follow up in our outpatient clinic. in those appointed time the patient will fill again The Pittsburgh Sleep Quality Index.
Study: NCT02204748

Intervention type: DEVICE
Intervention: DePuy Attune posterior stabilizing fixed bearing knee system
Study: NCT03488277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: leg elevation
Description: intra operative position that consists in leg elevation with a 30 cm height pillow under the patient's heels
Study: NCT04797351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy - Skills
Description: Pre-treatment session + 12 sessions DBT Skills Group (only) intervention
Study: NCT04483609

Intervention type: OTHER
Intervention: Questionnaire administration pre test
Description: After the translation and cultural adaptation of the SF-Qualiveen scale is completed, face-to-face pre-test will be performed on 10 patients with multiple sclerosis.
Study: NCT00162565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beta-blocker treatment
Description: beta-blocker treatment
Study: NCT02865031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decorin
Description: Intravitreal Injection following ocular trauma to prevent scar tissue formation.
Study: NCT04657497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOY-305
Description: Specified Dosage and Duration of Treatment
Study: NCT04483609

Intervention type: OTHER
Intervention: Questionnaire administration validation and reliability
Description: After the pre-test is completed, if necessary, arrangements will be made, and then the validity and reliability of SF-Qualiveen will be made in 80 individuals with Multiple Sclerosis.First of all, participants will be asked to complete two questionnaires (SF-Qualiveen and Urinary Distress Inventory). Two weeks after this assessment, they will be asked to respond to SF-Qualiveen again.
Study: NCT01584362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxfendazole
Description: administration of a single oral 1.0 mg/kg dose of oxfendazole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single oral dose of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxfendazole
Description: administration of a single oral 3.0 mg/kg dose of oxfendazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxfendazole
Description: administration of a single oral 0.3 mg/kg dose of oxfendazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxfendazole
Description: administration of a single oral 10 mg/kg dose of oxfendazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxfendazole
Description: administration of a single oral 20 mg/kg dose of oxfendazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxfendazole
Description: administration of a single oral 30 mg/kg dose of oxfendazole
Study: NCT03002883

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participant provided Quit Kit water bottle with small cessation aids (eg. sunflower seeds) and educated about student health as a cessation resource

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participant provided Quit Kit water bottle with small cessation aids (eg. sunflower seeds) and educated about student health as a cessation resource

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Participant provided Quit Kit water bottle with small cessation aids (eg. sunflower seeds) and educated about student health as a cessation resource
Study: NCT01401179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefazolin, erythromycin, clarithromycin
Description: Antibiotics regimen was one of cefazolin or cefazolin plus erythromycin or cefazolin plus clarithromycin. Intravenous 1g cefazolin was given every 6 hours after negative result skin test for allergic reaction. With cefazolin plus erythromycin group or cefazolin plus clarithromycin, cefazolin was given with same protocol and 250mg oral erythromycin every 6 hours or 500mg oral clarithromycin every 12 hours was added. All antibiotics were given for 7 days or until delivery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefazolin, erythromycin, clarithromycin
Description: Antibiotics regimen was one of cefazolin or cefazolin plus erythromycin or cefazolin plus clarithromycin. Intravenous 1g cefazolin was given every 6 hours after negative result skin test for allergic reaction. With cefazolin plus erythromycin group or cefazolin plus clarithromycin, cefazolin was given with same protocol and 250mg oral erythromycin every 6 hours or 500mg oral clarithromycin every 12 hours was added. All antibiotics were given for 7 days or until delivery.
Study: NCT01784094

Intervention type: DEVICE
Intervention: StromaGlide

Intervention type: DEVICE
Intervention: StromaGlide
Study: NCT06133361

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP injection
Description: The PRP will be prepared according to a well-established technique and then injected into the palatal mucosa of the upper anterior teeth before retraction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: En-masse retraction of upper anterior teeth
Description: The anterior teeth will be moved backward in an en-masse retraction way using a frictionless method. The anterior teeth will be manipulated as one block. Coil springs will be stretched between the power arms (in the anterior area) to the miniscrews placed in the posterior area bilaterally.
Study: NCT04469140

Intervention type: DEVICE
Intervention: SS-OCT imaging
Description: All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument
Study: NCT00795652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distance Treatment for postpartum depression
Description: Evidence-based, cognitive behavioural intervention for women with postpartum depression
Study: NCT03307226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Development Accounts (YDA)
Description: Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development Financial workshops on asset-building, saving and investing in Income Generating Activities (IGAs) Behavioral: Youth Development Accounts (YDA)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YDA + Multiple Family Groups (MFG)
Description: Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development 12 Financial Management workshops on asset-building, saving and investing in Income Generating Activities (IGAs) 18 Multiple Family Groups sessions focused on strengthening family relationships and mental health
Study: NCT04215237

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin 20 Mg Oral Tablet
Description: Atorvastatin 20mg oral once a day
Study: NCT03002883

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Interviewing
Description: Peer educator conducts brief motivational interviewing about smoking cessation and participant goals

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Direct referral to quitline
Description: Peer educator educates about state quitline services and gets verbal consent to use quitline's direct referral web portal for quitline to contact participant in 1-2 business days about free counseling services to make a quit plan
Study: NCT00682526

Intervention type: DEVICE
Intervention: SmartLink Wireless Monitoring System (K033642)
Description: All EMS transported patients age 18 or over who have their ECG attempted to be wirelessly transmitted and with the intention to treat with coronary reperfusion therapy (PCI or thrombolytics)based on their initial presentation.

Intervention type: DEVICE
Intervention: SmartLink Wireless Monitoring System (K033642)
Description: All EMS transported patients age 18 or over who have their ECG attempted to be wirelessly transmitted and with the intention to treat with coronary reperfusion therapy (PCI or thrombolytics)based on their initial presentation.
Study: NCT02399657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone 0.7mg implant
Description: Ozurdex at day 0 (fixed), 5 months (fixed), 10 months pro re nata or 11 months pro re nata
Study: NCT02962986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Norepinephrine diluted in 5% dextrose solution to a concentration of 6mcg/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Phenylephrine diluted in 0.9% normal saline solution to a concentration of 100mcg/mL
Study: NCT00428272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexatumumab alone
Description: Dose escalation : 3mg/kg, 5mg/kg, 8mg/kg, 10mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexatumumab in combination
Description: Dose escalation : 1mg/kg, 3mg/kg, 5mg/kg, 8mg/kg, 10mg/kg

Intervention type: DRUG
Group type: OTHER
Intervention: Lexatumumab in combination
Description: Dose escalation : 1mg/kg, 3mg/kg, 5mg/kg, 8mg/kg, 10mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon gamma 1b in combination
Description: Dosing at the following for each lexatumumab dose level: .75mcg/m2/dose and 25mcg/m2/dose
Study: NCT00718692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym001
Description: Each cohort will receive one single dose of Sym001 according the assigned dose level.
Study: NCT03451123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FET PET/MRI
Description: FET PET/MRI scan before and after surgery
Study: NCT04979611

Intervention type: DRUG
Group type: OTHER
Intervention: 68Ga-NOTA-exendin-4
Description: A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be injected intravenously
Study: NCT00428272

Intervention type: DRUG
Group type: OTHER
Intervention: Gamma 1b potential expansion
Description: Potential expansion (at 10mg/kg lexatumumab): 1.5mcg/m2/dose and 50mcg/m2/dose
Study: NCT03274856

Intervention type: DRUG
Group type: OTHER
Intervention: GLWL-01
Description: Oral administration of 3 capsules, twice a day

Intervention type: DRUG
Group type: OTHER
Intervention: GLWL-01
Description: Oral administration of 3 capsules, twice a day
Study: NCT01570478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foster® NEXThaler® 100/6 µg/unit dose
Description: Foster® NEXThaler® (beclomethasone dipropionate 100 µg plus formoterol 6 µg per actuation), 2 inhalations b.i.d. (daily dose of BDP 400 µg plus FF 24 µg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide® Accuhaler® 250/50 µg/actuation
Description: Seretide® Accuhaler® (fluticasone propionate 250 μg plus salmeterol xinafoate 50 μg per actuation), 1 inhalation b.i.d. (daily dose of fluticasone 500 μg plus salmeterol 100 μg)
Study: NCT04018378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline tartrate 1mg (HGP1604, R) - varenicline oxalate 1mg (HIP1502, T), RT
Description: varenicline tartrate 1mg (HGP1604) was used as a reference drug and varenicline oxalate 1mg (HIP1502) was used as a test drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline oxalate 1mg (HIP1502, T) - varenicline tartrate 1mg (HGP1604, R), TR
Description: varenicline tartrate 1mg (HGP1604) was used as a reference drug and varenicline oxalate 1mg (HIP1502) was used as a test drug.
Study: NCT03274856

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Oral administration of 3 capsules, twice a day

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Oral administration of 3 capsules, twice a day
Study: NCT01200173

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: 2-Non fermented dairy product (control)
Study: NCT01412788

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peri-areolar incision
Description: peri-areolar incision was used to carry out lumpectomy in breast-conserving surgery.
Study: NCT04469140

Intervention type: DEVICE
Intervention: SS-OCT imaging
Description: All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument

Intervention type: DEVICE
Intervention: SS-OCT imaging
Description: All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument
Study: NCT04246996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gentamicin sulfate
Description: Subjects in the gentamicin arm will receive an bladder instillation of 80mg of gentamicin sulfate in 50 mL of normal saline through a standard-of-care Foley catheter.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Catheter clamping only
Description: Subjects in the control arm will have their standard-of-care transurethral catheter clamped for 1 hour post-placement to maintain subject masking to study arm.
Study: NCT00866021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: NRTI sparing-regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir with two nucleoside analogs
Description: LPV/r plus 2NRTIs + PEG-INF + RBV
Study: NCT01412788

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional incision
Description: Traditional incision above tumor was used to carry out breast-conserving surgery.
Study: NCT00932867

Intervention type: DRUG
Intervention: Kinzal/Pritor (Telmisartan, BAY68-9291)
Description: Patients under daily life treatment receiving Pritor according to local drug information.